About revumenib
Menin inhibitor anticancer medicine
Used for
- Treats certain relapsed or refractory acute leukemia with a KMT2A translocation in adults and children.
- Treats certain relapsed or refractory acute myeloid leukemia with an NPM1 mutation in adults.
Usual adult dose
Usual dose is 270 mg by mouth twice daily; some patients taking strong CYP3A4 inhibitors use 160 mg twice daily. Treatment is specialist-directed.
Usual dose in children
For children aged 1 year and older, dose is based on body surface area, typically twice daily; specialist-directed dosing is required.
Common side effects
- Nausea, vomiting, diarrhea, and reduced appetite
- Low blood counts, including anemia, low platelets, or low white cells
- Changes in liver blood tests
- QT prolongation, a heart rhythm abnormality
Important warnings
- Can cause differentiation syndrome, which may be life-threatening; urgent assessment is needed for fever, breathing problems, swelling, or rapid weight gain.
- Can prolong the QT interval and cause dangerous heart rhythms; monitoring is required.
- Blood counts, liver tests, and electrolytes require monitoring during treatment.
- Avoid grapefruit and review all medicines for interactions before use.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for four months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can raise revumenib levels; dose adjustment may be needed.
- Strong CYP3A4 inducers can reduce revumenib levels; avoid use when possible.
- Revumenib can affect levels of some CYP3A4-substrate medicines; monitoring or dose changes may be needed.
- Other medicines that prolong the QT interval may increase heart rhythm risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.